^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AU7R-104

    i
    Other names: AU7R-104, AUR-104
    Associations

    News

    Trials
    Company:
    Dr. Reddy’s
    Drug class:
    CD47 inhibitor
    Related drugs:
    Associations

    News

    Trials
    over3years
    [VIRTUAL] Discovery and preclinical evaluation of a novel covalent inhibitor of FABP5 for cancer therapy (AACR 2021)
    In summary, we have identified a novel covalent FABP5 inhibitor with optimized properties that showed anti-tumor activity in in vitro and in vivo models with acceptable safety profile. The data presented here strongly support clinical development of AUR104.
    Preclinical
    |
    IL6 (Interleukin 6) • IL10 (Interleukin 10) • MALT1 (MALT1 Paracaspase)
    |
    AU7R-104